Santaris Pharma A/S is rapidly becoming the preferred partner for the development of RNA-targeted medicines having established partnerships with five pharmaceutical companies over the past five years. These partnerships further validate the broad utility of the Santaris Pharma A/S LNA Drug Platform and Drug Discovery Engine to develop effective and well tolerated LNA-based drugs across multiple disease areas for its partners.
The LNA Drug Platform offers access to clinical pathways that have been previously inaccessible. The potential of the LNA Drug Platform and Drug Discovery Engine is evidenced by the number of drugs currently under development and the impressive roster of strategic partners. Santaris Pharma A/S, using the LNA Drug Platform, is the only company to have advanced both mRNA and microRNA targeted drugs into clinical trials, reinforcing the strength and utility of the platform.